Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Dec;81(8):1280–1284. doi: 10.1038/sj.bjc.6694366

Human cultured dendritic cells show differential sensitivity to chemotherapy agents as assessed by the MTS assay

D Chao 1, P Bahl 1, S Houlbrook 2, L Hoy 1, A L Harris 2, J M Austyn 1
PMCID: PMC2362963  PMID: 10604723

Abstract

Assessment of the chemosensitivity of dendritic cells (DC) may allow more rational development of combined chemotherapy and immunotherapy protocols. Human monocyte-derived DC generated reproducible results in the MTS (Owen’s reagent) assay, which was then used to study DC survival after treatment with four different chemotherapy agents. DC preparations from three different donors were used per drug. DC were sensitive to doxorubicin (concentration range 0.1–50 μM) with variation in sensitivity between donors (IC50 244–1100 nM). The most extreme variation was seen for vinblastine (concentration range 250–0.025 μM with IC50 0.15–17.25 μM). In contrast, there was relative resistance to etoposide (concentration range 0.2–200 μM) and 5-fluorouracil (concentration range 0.7–7700 μM) with no toxicity seen until 50 μM and 770 μM respectively. The function of DC in allogeneic mixed leucocyte reactions closely paralleled results from the MTS assays. The differential sensitivity to chemotherapy agents did not appear to be due to expression of P-glycoprotein. These results suggest that etoposide or 5-fluorouracil is less likely to reduce the immunotherapeutic potential of DC and may be valuable in the design of prodrug activation therapy. © 1999 Cancer Research Campaign

Keywords: human, dendritic cell, chemotherapy, MTS, immunotherapy

Full Text

The Full Text of this article is available as a PDF (121.2 KB).

Footnotes

Dr David Chao is a Medical Research Council Clinical Training Fellow.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albert M. L., Sauter B., Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998 Mar 5;392(6671):86–89. doi: 10.1038/32183. [DOI] [PubMed] [Google Scholar]
  2. Austyn J. M. Dendritic cells. Curr Opin Hematol. 1998 Jan;5(1):3–15. doi: 10.1097/00062752-199801000-00002. [DOI] [PubMed] [Google Scholar]
  3. Bender A., Sapp M., Schuler G., Steinman R. M., Bhardwaj N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods. 1996 Sep 27;196(2):121–135. doi: 10.1016/0022-1759(96)00079-8. [DOI] [PubMed] [Google Scholar]
  4. Berger W., Elbling L., Hauptmann E., Micksche M. Expression of the multidrug resistance-associated protein (MRP) and chemoresistance of human non-small-cell lung cancer cells. Int J Cancer. 1997 Sep 26;73(1):84–93. doi: 10.1002/(sici)1097-0215(19970926)73:1<84::aid-ijc14>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  5. Cory A. H., Owen T. C., Barltrop J. A., Cory J. G. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 1991 Jul;3(7):207–212. doi: 10.3727/095535491820873191. [DOI] [PubMed] [Google Scholar]
  6. Fraile R. J., Baker L. H., Buroker T. R., Horwitz J., Vaitkevicius V. K. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res. 1980 Jul;40(7):2223–2228. [PubMed] [Google Scholar]
  7. Greene R. F., Collins J. M., Jenkins J. F., Speyer J. L., Myers C. E. Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Res. 1983 Jul;43(7):3417–3421. [PubMed] [Google Scholar]
  8. Henwood J. M., Brogden R. N. Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Drugs. 1990 Mar;39(3):438–490. doi: 10.2165/00003495-199039030-00008. [DOI] [PubMed] [Google Scholar]
  9. Melcher A., Todryk S., Hardwick N., Ford M., Jacobson M., Vile R. G. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med. 1998 May;4(5):581–587. doi: 10.1038/nm0598-581. [DOI] [PubMed] [Google Scholar]
  10. Mullen C. A., Kilstrup M., Blaese R. M. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):33–37. doi: 10.1073/pnas.89.1.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Nelson R. L., Dyke R. W., Root M. A. Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer. Cancer Treat Rev. 1980 Sep;7 (Suppl 1):17–24. doi: 10.1016/s0305-7372(80)80003-x. [DOI] [PubMed] [Google Scholar]
  12. Nestle F. O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G., Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998 Mar;4(3):328–332. doi: 10.1038/nm0398-328. [DOI] [PubMed] [Google Scholar]
  13. Randolph G. J., Beaulieu S., Pope M., Sugawara I., Hoffman L., Steinman R. M., Muller W. A. A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels. Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6924–6929. doi: 10.1073/pnas.95.12.6924. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Romani N., Reider D., Heuer M., Ebner S., Kämpgen E., Eibl B., Niederwieser D., Schuler G. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods. 1996 Sep 27;196(2):137–151. doi: 10.1016/0022-1759(96)00078-6. [DOI] [PubMed] [Google Scholar]
  15. Rubartelli A., Poggi A., Zocchi M. R. The selective engulfment of apoptotic bodies by dendritic cells is mediated by the alpha(v)beta3 integrin and requires intracellular and extracellular calcium. Eur J Immunol. 1997 Aug;27(8):1893–1900. doi: 10.1002/eji.1830270812. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES